Tyrosine kinase receptor expression in thymomas

Research output: Contribution to journalArticle

72 Citations (Scopus)

Abstract

Purpose: Promising new therapies for neoplasia include tyrosine kinase receptor antagonists. Tyrosine kinase oncogenes present an appealing anti-tumor drug target since they play an integral role in a variety of cellular responses including cell proliferation and differentiation. We previously demonstrated a high rate of epidermal growth factor receptor (EGFR) expression in advanced-stage thymic epithelial tumors. More recently, we have examined c-KIT (CD117) expression in a similar series of tumors. Methods: Tumor from 35 patients seen at our institution for treatment of advanced-stage thymoma was available. Twenty thymomas and 15 thymic carcinomas were assessed for c-KIT expression. Tissue sections of tumor were stained immunohistochemically with anti-c-KIT (Oncogene). Either cytoplasmic or membrane staining was considered positive. Appropriate controls were performed. Positive staining for c-KIT was present in 12 tumors (11 thymic carcinomas and 1 thymoma). Results: In distinction to EGFR, c-KIT is expressed more commonly in thymic carcinomas (73% of carcinomas) than in thymoma (5% of thymomas). Conclusions: An EGFR negative/c-KIT positive staining pattern is typical of thymic carcinoma, whereas thymomas are generally EGFR positive/c-KIT negative. Possible therapeutic implications of these observations remain to be determined.

Original languageEnglish
Pages (from-to)222-224
Number of pages3
JournalJournal of Cancer Research and Clinical Oncology
Volume130
Issue number4
DOIs
StatePublished - Apr 2004

Fingerprint

Thymoma
Receptor Protein-Tyrosine Kinases
Epidermal Growth Factor Receptor
Neoplasms
Staining and Labeling
Oncogenes
Protein-Tyrosine Kinases
Cell Differentiation
Therapeutics
Cell Proliferation
Cell Membrane
Carcinoma

Keywords

  • c-KIT
  • CD 117
  • Thymic carcinoma
  • Thymoma
  • Tyrosine kinase

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Tyrosine kinase receptor expression in thymomas. / Henley, John D.; Cummings, Oscar; Loehrer, Patrick.

In: Journal of Cancer Research and Clinical Oncology, Vol. 130, No. 4, 04.2004, p. 222-224.

Research output: Contribution to journalArticle

@article{b14b95fa9ec14da895e5e35e5db6b409,
title = "Tyrosine kinase receptor expression in thymomas",
abstract = "Purpose: Promising new therapies for neoplasia include tyrosine kinase receptor antagonists. Tyrosine kinase oncogenes present an appealing anti-tumor drug target since they play an integral role in a variety of cellular responses including cell proliferation and differentiation. We previously demonstrated a high rate of epidermal growth factor receptor (EGFR) expression in advanced-stage thymic epithelial tumors. More recently, we have examined c-KIT (CD117) expression in a similar series of tumors. Methods: Tumor from 35 patients seen at our institution for treatment of advanced-stage thymoma was available. Twenty thymomas and 15 thymic carcinomas were assessed for c-KIT expression. Tissue sections of tumor were stained immunohistochemically with anti-c-KIT (Oncogene). Either cytoplasmic or membrane staining was considered positive. Appropriate controls were performed. Positive staining for c-KIT was present in 12 tumors (11 thymic carcinomas and 1 thymoma). Results: In distinction to EGFR, c-KIT is expressed more commonly in thymic carcinomas (73{\%} of carcinomas) than in thymoma (5{\%} of thymomas). Conclusions: An EGFR negative/c-KIT positive staining pattern is typical of thymic carcinoma, whereas thymomas are generally EGFR positive/c-KIT negative. Possible therapeutic implications of these observations remain to be determined.",
keywords = "c-KIT, CD 117, Thymic carcinoma, Thymoma, Tyrosine kinase",
author = "Henley, {John D.} and Oscar Cummings and Patrick Loehrer",
year = "2004",
month = "4",
doi = "10.1007/s00432-004-0545-z",
language = "English",
volume = "130",
pages = "222--224",
journal = "Journal of Cancer Research and Clinical Oncology",
issn = "0171-5216",
publisher = "Springer Verlag",
number = "4",

}

TY - JOUR

T1 - Tyrosine kinase receptor expression in thymomas

AU - Henley, John D.

AU - Cummings, Oscar

AU - Loehrer, Patrick

PY - 2004/4

Y1 - 2004/4

N2 - Purpose: Promising new therapies for neoplasia include tyrosine kinase receptor antagonists. Tyrosine kinase oncogenes present an appealing anti-tumor drug target since they play an integral role in a variety of cellular responses including cell proliferation and differentiation. We previously demonstrated a high rate of epidermal growth factor receptor (EGFR) expression in advanced-stage thymic epithelial tumors. More recently, we have examined c-KIT (CD117) expression in a similar series of tumors. Methods: Tumor from 35 patients seen at our institution for treatment of advanced-stage thymoma was available. Twenty thymomas and 15 thymic carcinomas were assessed for c-KIT expression. Tissue sections of tumor were stained immunohistochemically with anti-c-KIT (Oncogene). Either cytoplasmic or membrane staining was considered positive. Appropriate controls were performed. Positive staining for c-KIT was present in 12 tumors (11 thymic carcinomas and 1 thymoma). Results: In distinction to EGFR, c-KIT is expressed more commonly in thymic carcinomas (73% of carcinomas) than in thymoma (5% of thymomas). Conclusions: An EGFR negative/c-KIT positive staining pattern is typical of thymic carcinoma, whereas thymomas are generally EGFR positive/c-KIT negative. Possible therapeutic implications of these observations remain to be determined.

AB - Purpose: Promising new therapies for neoplasia include tyrosine kinase receptor antagonists. Tyrosine kinase oncogenes present an appealing anti-tumor drug target since they play an integral role in a variety of cellular responses including cell proliferation and differentiation. We previously demonstrated a high rate of epidermal growth factor receptor (EGFR) expression in advanced-stage thymic epithelial tumors. More recently, we have examined c-KIT (CD117) expression in a similar series of tumors. Methods: Tumor from 35 patients seen at our institution for treatment of advanced-stage thymoma was available. Twenty thymomas and 15 thymic carcinomas were assessed for c-KIT expression. Tissue sections of tumor were stained immunohistochemically with anti-c-KIT (Oncogene). Either cytoplasmic or membrane staining was considered positive. Appropriate controls were performed. Positive staining for c-KIT was present in 12 tumors (11 thymic carcinomas and 1 thymoma). Results: In distinction to EGFR, c-KIT is expressed more commonly in thymic carcinomas (73% of carcinomas) than in thymoma (5% of thymomas). Conclusions: An EGFR negative/c-KIT positive staining pattern is typical of thymic carcinoma, whereas thymomas are generally EGFR positive/c-KIT negative. Possible therapeutic implications of these observations remain to be determined.

KW - c-KIT

KW - CD 117

KW - Thymic carcinoma

KW - Thymoma

KW - Tyrosine kinase

UR - http://www.scopus.com/inward/record.url?scp=2142642249&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=2142642249&partnerID=8YFLogxK

U2 - 10.1007/s00432-004-0545-z

DO - 10.1007/s00432-004-0545-z

M3 - Article

C2 - 14762710

AN - SCOPUS:2142642249

VL - 130

SP - 222

EP - 224

JO - Journal of Cancer Research and Clinical Oncology

JF - Journal of Cancer Research and Clinical Oncology

SN - 0171-5216

IS - 4

ER -